Phase II/III Study Comparing Chemoradiotherapy With Radiotherapy in Elderly Patients With Esophageal or Esophagogastric Cancer - 3JECROG P-01

• Status: Completed
• Trial end date: 2020-04-01
• Target enrollment: 0
• Participant gender: All

Summary

Ratiotherapy alone is the current standard treatment for elderly esophageal or esophagogastric cancer in China. And Little is known about chemoradiotherapy (CRT) in elderly patients. This study aimed to assess the efficiency and safety of simultaneous integrated boost (SIB) intensity modulated radiation therapy (IMRT) with S1 based SIB-IMRT followed by adjuvant chemotherapy with S1 in in elderly (age ≥70 years) esophageal or esophagogastric cancer patients

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Chinese Academy of Medical Sciences
• Collaborators: Affiliated Hospital of Hebei University; Anyang Tumor Hospital; Fujian Cancer Hospital; Hebei Medical University Fourth Hospital; Sichuan Cancer Hospital and Research Institute; Tengzhou Central People's Hospital; The Affiliated Hospital of Inner Mongolia Medical University; The First Affiliated Hospital of Zhengzhou University; The First Affiliated Hospital with Nanjing Medical University; Tianjin Medical University Cancer Institute and Hospital

Criteria

Inclusion Criteria:

• ≥70 years

• Esophageal or Esophagogastric cancer

• Histologically proven squamous cell carcinoma or adenocarcinoma in patients staged as IIa-IVb (UICC 2002, IVb only with supraclavicular or celiac trunk lymph nodes metastasis)

• Karnofsky performance status(KPS)≥ 70 and Charlson score ≤3

• No distant metastasis other than supraclavicular lymph nodes

• No prior history of thoracic radiation

• Patients must have normal organ and marrow function as defined below: Leukocytes:

greater than or equal to 3,500 G/L; Platelets: greater than or equal to 100,000/mm3 .Hemoglobin:greater than or equal to 10g/L .Total bilirubin: within normal institutional limits; AST/ALT: less than or equal to 1.5 times the upper limit; Creatinine within normal upper limits

• Informed consent

Exclusion Criteria:

• Patients with other cancer history except cervical carcinoma in situ and non-malignant melanoma skin cancer

• With any distant metastasis out of regional lymphatic drainage or in liver,lung,bone,CNS,etc

• History of allergic reactions attributed to similar chemical or biologic complex to S-1

• With esophageal fistula, perforation, cachexia prior to treatment

• Uncontrolled illness including, but not limited to, active infection, symptomatic heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness

• History of myocardial infarction within the past 6 months or history of ventricular arrhythmia

• Pregnant or lactating females